MAP2K2 and melanoma: Trametinib (GSK1120212) is an oral non–ATP-competitive MEK1 and MEK2 inhibitor previously approved for combinatorial therapy in melanoma and efficacious in patients with CLAs (20–25) (Supplemental Table 1).